Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
INCY · Nasdaq · United States · Services-Commercial Physical & Biological Research
In shortINCYTE CORP is profitable.
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 29.5% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 25.0% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 29.9% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.32× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 623.91× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 7.90 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 27.5% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.10× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 4.6% | 94/100 |
| Operating margin volatility | 10.1% | 18/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 14.8% | 99/100 |
|---|---|---|
| EPS growth, 3-year average | 61.6% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 2,986 | 3,395 | 3,696 | 4,241 | 5,141 |
| Cost of revenue | 151 | 207 | 255 | 312 | 372 |
| Gross profit | 2,835 | 3,188 | 3,441 | 3,929 | 4,769 |
| Research & development | 1,458 | 1,586 | 1,628 | 2,607 | 2,050 |
| Selling, general & admin | 740 | 1,002 | 1,156 | 1,242 | 1,376 |
| Operating income | 586 | 579 | 621 | 61 | 1,515 |
| Interest expense | 1.9 | 2.7 | 2.6 | 2.3 | 2.4 |
| Pre-tax income | 570 | 529 | 834 | 317 | 1,664 |
| Income tax | (378) | 188 | 237 | 284 | 378 |
| Net income | 949 | 341 | 598 | 33 | 1,287 |
| Diluted EPS | $4.27 | $1.52 | $2.65 | $0.15 | $6.41 |
| Diluted shares (millions) | 222 | 224 | 226 | 211 | 201 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
7.90 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Apr 28, 2026